Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations

In VitroActivity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014

(2016) Michael D. Huband et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of Ceftazidime-Avibactam against 338 Molecularly Characterized Gentamicin-Nonsusceptible Gram-Negative Clinical Isolates Obtained from Patients in Canadian Hospitals

(2015) Andrew J. Denisuik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Variants of β-Lactamase KPC-2 That Are Resistant to Inhibition by Avibactam

(2015) Krisztina M. Papp-Wallace et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-Avibactam Activity Tested against Enterobacteriaceae Isolates from U.S. Hospitals (2011 to 2013) and Characterization of β-Lactamase-Producing Strains

(2015) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013

(2015) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

(2015) Joseph Solomkin et al.   CLINICAL INFECTIOUS DISEASES

Effect of Age and Sex on the Pharmacokinetics and Safety of Avibactam in Healthy Volunteers

(2015) Antoine Tarral et al.   CLINICAL THERAPEUTICS

Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals

(2015) Christina A. Sutherland et al.   CLINICAL THERAPEUTICS

Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011–2014)

(2015) Helio S. Sader et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study

(2015) Marta Tato et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia

(2015) Helio S. Sader et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)

(2015) Florian M Wagenlehner et al.   LANCET

Mutation-Driven β-Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible Pseudomonas aeruginosa Isolates from U.S. Hospitals

(2014) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections

(2014) Christopher Lucasti et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroSusceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations

(2014) Henry Li et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosa

(2014) Marisa L. Winkler et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011)

(2014) Robert K. Flamm et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

New Delhi Metallo-beta-lactamase around the world: An eReview using Google Maps

(2014) M Berrazeg et al.   Eurosurveillance

Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009–2012

(2014) Helio S. Sader et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)

(2014) David J. Farrell et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12)

(2014) Helio S. Sader et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)

(2014) R. K. Flamm et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Activity of Ceftolozane-Tazobactam as Determined by Broth Dilution and Agar Diffusion Assays against Recent U.S. Escherichia coli Isolates from 2010 to 2011 Carrying CTX-M-Type Extended-Spectrum  -Lactamases

(2014) M. Estabrook et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections

(2014) Gurudatt Chandorkar et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)

(2014) Helio S. Sader et al.   JOURNAL OF INFECTION

In VitroActivity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals in the CANWARD Study, 2007 to 2012

(2013) A. Walkty et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)

(2013) David J. Farrell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Ceftolozane-Tazobactam against a Broad Spectrum of Recent Clinical Anaerobic Isolates

(2013) David R. Snydman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012

(2013) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mermel LA (Clin Infect Dis 2013; 56:123-30)

(2013)   CLINICAL INFECTIOUS DISEASES

Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes

(2013) David van Duin et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

The Effect of a Hospital-Wide Urine Culture Screening Intervention on the Incidence of Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella Species

(2013) Jennifer H. Han et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial

(2013) Christopher Lucasti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam

(2013) Shampa Das et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases

(2013) L Silvia Munoz-Price et al.   LANCET INFECTIOUS DISEASES

Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses

(2012) Benjamin Miller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroAntibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates

(2012) Premavathy Levasseur et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study

(2012) José A. Vazquez et al.   CURRENT MEDICAL RESEARCH AND OPINION

Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole

(2012) L.J. Dubreuil et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects

(2012) G. Chandorkar et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Avibactam is a covalent, reversible, non- -lactam  -lactamase inhibitor

(2012) D. E. Ehmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study)

(2011) A. Walkty et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of the  -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases

(2009) T. Stachyra et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

(2008) Helen W. Boucher et al.   CLINICAL INFECTIOUS DISEASES

Structural requirements for the stability of novel cephalosporins to AmpC β-lactamase based on 3D-structure

(2007) Kenji Murano et al.   BIOORGANIC & MEDICINAL CHEMISTRY